{
    "1": {
        "question": "How many studies are in cBioPortal?",
        "response_brief": {
            "missing_steps": [],
            "extra_steps": [],
            "steps_to_queries_mapping": {
                "1": "1"
            },
            "completeness": 3,
            "conciseness": 3,
            "correctness": 3,
            "comments": "The LLM output perfectly matches the expected step. Query 1 directly counts the total number of studies from the cancer_study table, which is exactly what step 1 requires. The SQL is straightforward and appropriate for the task."
        },
        "response_detailed": {
            "missing_steps": [],
            "extra_steps": [],
            "steps_to_queries_mapping": {
                "1": "1"
            },
            "completeness": 3,
            "conciseness": 3,
            "correctness": 3,
            "comments": "The LLM output perfectly matches the expected step. It executes a single SQL query that counts rows in the 'cancer_study' table, which directly corresponds to the expected step of counting studies in cBioPortal. The query is correct and efficient."
        }
    },
    "2": {
        "question": "How many patients and samples are in the MSK-CHORD Study?",
        "response_brief": {
            "missing_steps": [],
            "extra_steps": [],
            "steps_to_queries_mapping": {
                "1": "1",
                "2": "2"
            },
            "completeness": 3,
            "conciseness": 3,
            "correctness": 3,
            "comments": "The LLM output perfectly follows the expected steps. Query 1 identifies the MSK-CHORD study by searching for it in the cancer_study table, and Query 2 counts the distinct number of patients and samples in that study. The queries are logically sound and directly correspond to the expected steps without any unnecessary operations."
        },
        "response_detailed": {
            "missing_steps": [],
            "extra_steps": [],
            "steps_to_queries_mapping": {
                "1": "1",
                "2": "2",
                "3": "2"
            },
            "completeness": 3,
            "conciseness": 3,
            "correctness": 3,
            "comments": "The LLM output correctly implements all expected steps. Query 1 identifies the MSK-CHORD study identifier, and Query 2 efficiently combines steps 2 and 3 by joining the sample and patient tables while filtering by the cancer study identifier and counting distinct patients and samples. The approach is both complete and concise, using LEFT JOINs appropriately to ensure all relationships are captured."
        }
    },
    "3": {
        "question": "How many primary samples are in the MSK-CHORD Study?",
        "response_brief": {
            "missing_steps": [],
            "extra_steps": [
                "Query 2: Exploring available attribute names",
                "Query 3: Checking for SAMPLE_TYPE attribute",
                "Query 4: First attempt with complex joins",
                "Query 5: Second attempt with different approach",
                "Query 6: Exploring all sample types for distribution"
            ],
            "steps_to_queries_mapping": {
                "1": "1",
                "2": "7"
            },
            "completeness": 3,
            "conciseness": 1,
            "correctness": 3,
            "comments": "All expected steps are present and correctly executed. The LLM identified the MSK-CHORD study (Query 1) and counted primary samples (Query 7). However, there are many exploratory queries (2-6) that, while showing good problem-solving approach, are not directly required by the expected steps. The final answer is correct with 15,928 primary samples."
        },
        "response_detailed": {
            "missing_steps": [],
            "extra_steps": [
                "Query 2: Exploring attribute names",
                "Query 3: Checking for SAMPLE_TYPE attribute",
                "Query 4: Complex join approach",
                "Query 5: Alternative counting approach",
                "Query 6: Breakdown by sample type"
            ],
            "steps_to_queries_mapping": {
                "1": "1",
                "2": "7"
            },
            "completeness": 3,
            "conciseness": 1,
            "correctness": 3,
            "comments": "All expected steps are present and correctly executed. Query 1 identifies the MSK-CHORD study identifier, and Query 7 counts primary samples. However, there are many exploratory and alternative queries (2-6) that, while potentially useful for verification, are not necessary for answering the core question. The final answer of 15,928 primary samples appears correct based on the query results."
        }
    },
    "4": {
        "question": "What treatment did most patients receive in the MSK-CHORD Study?",
        "response_brief": {
            "missing_steps": [],
            "extra_steps": [
                "Query 2: Checking clinical attributes for treatment fields",
                "Query 3: Listing all clinical attributes",
                "Query 5: Exploring attribute names and values",
                "Query 6: Exploring key-value pairs",
                "Query 8: Counting total patients with treatment",
                "Query 9: Counting total patients in study"
            ],
            "steps_to_queries_mapping": {
                "1": "1",
                "2": "4",
                "3": "7,10",
                "4": "7,10"
            },
            "completeness": 3,
            "conciseness": 2,
            "correctness": 3,
            "comments": "All expected steps are present and correctly executed. The LLM identified the MSK-CHORD study, retrieved treatment-related clinical events, grouped by treatment type, and determined the most common treatments. However, there are several exploratory queries that, while helpful for understanding the data structure, are not strictly necessary for answering the core question. The final analysis correctly identifies chemotherapy as the most common treatment modality and provides detailed breakdowns by specific agents."
        },
        "response_detailed": {
            "missing_steps": [],
            "extra_steps": [
                "Query 2: Exploring clinical attributes for treatment fields",
                "Query 3: Listing all clinical attributes",
                "Query 4: Finding distinct event types",
                "Query 5: Exploring attribute names and values",
                "Query 6: Exploring key-value pairs",
                "Query 8: Counting total patients with treatment",
                "Query 9: Getting total patients in study"
            ],
            "steps_to_queries_mapping": {
                "1": "1",
                "2": "7,10",
                "3": "7,10",
                "4": "7,10"
            },
            "completeness": 3,
            "conciseness": 1,
            "correctness": 3,
            "comments": "All expected steps are present and correctly executed. Query 1 finds the MSK-CHORD study identifier. Queries 7 and 10 retrieve treatment data, group by treatment types/agents, count distinct patients, and identify the most common treatments. However, there are many exploratory queries (2,3,4,5,6,8,9) that don't directly correspond to the expected steps, significantly reducing conciseness. The final analysis correctly identifies chemotherapy and specific agents like Fluorouracil as the most common treatments."
        }
    },
    "5": {
        "question": "What are the top 5 most frequently mutated genes in the Osteosarcoma study from TARGET?",
        "response_brief": {
            "missing_steps": [
                "Step 4: Calculate mutation frequency as a percentage of all samples with mutation data in the study"
            ],
            "extra_steps": [],
            "steps_to_queries_mapping": {
                "1": "1",
                "2": "2",
                "3": "2",
                "4": "3",
                "5": "2"
            },
            "completeness": 2,
            "conciseness": 3,
            "correctness": 2,
            "comments": "The LLM correctly identifies the TARGET Osteosarcoma study, retrieves mutation data, counts mutations per gene, gets total sample count, and identifies top 5 genes. However, the frequency calculation as a percentage is done in the presentation layer rather than in SQL. The frequency calculation logic also appears incorrect - it should be (mutated_samples/total_samples_with_mutation_data)*100, but the percentages shown don't match this formula given the numbers provided."
        },
        "response_detailed": {
            "missing_steps": [
                "Step 6: Calculate the mutation frequency for each of the top five genes by dividing the counts from step 4 by the total number of samples from step 5, and multiplying by 100 to get a percentage"
            ],
            "extra_steps": [],
            "steps_to_queries_mapping": {
                "1": "1",
                "2": "2",
                "3": "2",
                "4": "2",
                "5": "3"
            },
            "completeness": 2,
            "conciseness": 3,
            "correctness": 3,
            "comments": "The LLM output correctly executes most expected steps through SQL queries. Steps 1-5 are properly addressed, but step 6 (calculating mutation frequency percentages) is performed in the analysis text rather than in SQL. The queries are efficient and logically sound, combining steps 2-4 into a single well-structured query. The final percentages shown in the results table indicate the calculation was done, just not within the SQL queries themselves."
        }
    },
    "6": {
        "question": "What fraction of patients were older than five when diagnosed according to the Pediatric Neuroblastoma study from TARGET?",
        "response_brief": {
            "missing_steps": [],
            "extra_steps": [
                "Query 2: Checking clinical attributes in multiple studies",
                "Query 3: Alternative approach to find clinical attributes",
                "Query 4: Using clinical_data_derived with attr_value column",
                "Query 5: Corrected version using attribute_value column",
                "Query 6: Exploring available attributes",
                "Query 7: Counting total records",
                "Query 8: Checking record types",
                "Query 9: Finding age-related attributes",
                "Query 10: Detailed age distribution breakdown"
            ],
            "steps_to_queries_mapping": {
                "1": "1",
                "2": "9",
                "3": "11",
                "4": "11",
                "5": "11"
            },
            "completeness": 3,
            "conciseness": 1,
            "correctness": 3,
            "comments": "All expected steps are covered and the final calculation is correct (125/1,076 = 11.6% patients older than 5). However, there are many exploratory queries that don't directly correspond to the expected steps, showing inefficient query execution. The LLM performed extensive database exploration before arriving at the correct solution."
        }
    },
    "7": {
        "question": "What is the most frequent mutation in the TP53 gene in the TCGA breast cancer study?",
        "response_brief": {
            "missing_steps": [
                "Step 4: Calculate the frequency of this mutation as a percentage of all samples with mutation data in the study"
            ],
            "extra_steps": [
                "Query 4: Additional breakdown of samples and mutations by study"
            ],
            "steps_to_queries_mapping": {
                "1": "1",
                "2": "2",
                "3": "3"
            },
            "completeness": 2,
            "conciseness": 2,
            "correctness": 3,
            "comments": "The LLM output successfully identifies TCGA breast cancer studies, retrieves TP53 mutation data, and identifies the most frequent mutation (R175H). However, it fails to calculate the percentage frequency as required in step 4. Query 4 provides additional context but doesn't address the missing percentage calculation. The overall approach and logic are sound."
        }
    },
    "8": {
        "question": "How many patients have an EGFR amplification in the TCGA Lung Adenocarcinoma study?",
        "response_brief": {
            "missing_steps": [],
            "extra_steps": [
                "Query 3: Total patient count calculation",
                "Query 4: Breakdown of CNA alteration levels"
            ],
            "steps_to_queries_mapping": {
                "1": "1",
                "2": "2",
                "3": "2",
                "4": "3"
            },
            "completeness": 3,
            "conciseness": 2,
            "correctness": 3,
            "comments": "All expected steps are covered by the queries. Query 1 identifies the TCGA lung adenocarcinoma study, Query 2 retrieves and counts patients with EGFR amplification, and Query 3 calculates the percentage by getting total patient count. Query 4 provides additional breakdown but wasn't strictly necessary for answering the question."
        }
    },
    "9": {
        "question": "Which KRAS mutations are most common in colorectal cancer?",
        "response_brief": {
            "missing_steps": [],
            "extra_steps": [
                "Query 1: Exploring available clinical attributes",
                "Query 2: Finding colorectal cancer types",
                "Query 3: Counting colorectal cancer samples",
                "Query 5: Counting total samples with KRAS data",
                "Query 8: Breaking down by study identifier"
            ],
            "steps_to_queries_mapping": {
                "1": "2,3",
                "2": "4,6,7",
                "3": "4,6,7",
                "4": "4,6,7"
            },
            "completeness": 3,
            "conciseness": 1,
            "correctness": 3,
            "comments": "All expected steps are covered but with significant redundancy. The LLM executed 8 queries when 2-3 would have sufficed. Queries 4, 6, and 7 essentially perform the same analysis with minor variations. The exploratory queries (1, 2, 3, 5, 8) provide additional context but aren't necessary for answering the core question. The logic is sound and results are accurate."
        }
    },
    "10": {
        "question": "What is the median survival time in the Osteosarcoma study from TARGET?",
        "response_brief": {
            "missing_steps": [
                "Step 4: Perform Kaplan-Meier analysis to determine the time at which survival drops below 50%"
            ],
            "extra_steps": [
                "Query 2: Check for survival-related attributes",
                "Query 3: List all clinical attributes",
                "Query 5: Count attribute values",
                "Query 6: Check data types",
                "Query 7: Recheck attribute values with different type case"
            ],
            "steps_to_queries_mapping": {
                "1": "1",
                "2": "2,3",
                "3": "8,9"
            },
            "completeness": 2,
            "conciseness": 1,
            "correctness": 2,
            "comments": "The LLM correctly identified the TARGET Osteosarcoma study, found survival attributes, and retrieved patient survival data. However, it calculated median survival using SQL median function instead of performing proper Kaplan-Meier analysis as required in Step 4. The approach includes many exploratory queries that don't directly correspond to expected steps, and the final median calculation doesn't account for censored data properly in survival analysis context."
        }
    },
    "11": {
        "question": "How does methylation of the MGMT gene promoter affect the prognosis and treatment response in patients with glioblastoma?",
        "response_brief": {
            "missing_steps": [],
            "extra_steps": [
                "Query 1-2: Searching for MGMT attributes",
                "Query 10: Listing all attributes",
                "Query 13-14: Checking other studies for MGMT data",
                "Query 16: Listing survival attributes"
            ],
            "steps_to_queries_mapping": {
                "1": "3,4,5",
                "2": "6,7,8,12,15,17",
                "3": "9,11"
            },
            "completeness": 3,
            "conciseness": 2,
            "correctness": 3,
            "comments": "All expected steps are covered comprehensively. The LLM identified glioblastoma studies with MGMT data, retrieved methylation status with survival outcomes, and compared treatment responses between methylated/unmethylated groups. Some extra exploratory queries were included but don't detract from the core analysis. The approach is methodical and produces clinically relevant insights about MGMT methylation's impact on prognosis and treatment response."
        }
    },
    "12": {
        "question": "For patients with the EML4-ALK fusion gene in lung cancer how do the different fusion variants affect their long-term quality of life and risk of developing a secondary cancer?",
        "response_brief": {
            "missing_steps": [
                "Step 0: No queries can be constructed to answer this question with the cBioPortal database"
            ],
            "extra_steps": [
                "Query 1: Search for quality of life attributes",
                "Query 2: Alternative search for quality attributes",
                "Query 3: Search for secondary cancer attributes",
                "Query 4: Find lung cancer studies",
                "Query 5: Search for EML4-ALK fusions in genomic events",
                "Query 6: Search for clinical attributes in lung studies",
                "Query 7: Search for specific clinical attributes",
                "Query 8: Query structural variants for EML4-ALK",
                "Query 9: Join EML4-ALK patients with clinical data",
                "Query 10: Count EML4-ALK patients by study",
                "Query 11: Find available clinical attributes for EML4-ALK patients",
                "Query 12: Search for time-related attributes",
                "Query 13: Check for secondary cancer data",
                "Query 14: Analyze survival by fusion variant",
                "Query 15: Check OS status values",
                "Query 16: Calculate mortality rates by fusion variant",
                "Query 17: Search clinical events for cancer/quality data",
                "Query 18: Alternative clinical events search",
                "Query 19: List all clinical event types"
            ],
            "steps_to_queries_mapping": {},
            "completeness": 1,
            "conciseness": 1,
            "correctness": 1,
            "comments": "The expected step clearly states that no queries can be constructed to answer this question with the cBioPortal database, indicating this is an out-of-scope question. However, the LLM proceeded to execute 19 queries attempting to find data on EML4-ALK fusion variants, quality of life, and secondary cancer outcomes. While the LLM correctly identified limitations in the data and acknowledged that quality of life and secondary cancer data are not available, it should have recognized upfront that this question cannot be answered with the available database and not executed any queries."
        }
    },
    "13": {
        "question": "For the TCGA pan-cancer cohort what is the survival difference and the corresponding statistical significance between patients with mutations in both TP53 and KRAS versus patients with only a KRAS mutation?",
        "response_brief": {
            "missing_steps": [
                "Step 6: Perform Kaplan-Meier survival analysis for both groups and calculate the log-rank test p-value to assess statistical significance"
            ],
            "extra_steps": [
                "Query 1: Identify TCGA studies (exploratory)",
                "Query 2: Find survival-related attributes (exploratory)",
                "Query 3: Count patients by study (exploratory)",
                "Query 4: Count patients with mutations by study (exploratory)",
                "Query 5: Initial attempt at mutation grouping",
                "Query 6: Sample mutation data exploration",
                "Query 7: Test mutation grouping logic",
                "Query 8: Refine mutation grouping",
                "Query 9: Further refine mutation grouping",
                "Query 14: Breakdown by cancer study"
            ],
            "steps_to_queries_mapping": {
                "1": "1,3",
                "2": "4,6,7,8,9",
                "3": "5,7,8,9",
                "4": "2",
                "5": "10,11,12,13"
            },
            "completeness": 2,
            "conciseness": 1,
            "correctness": 2,
            "comments": "The LLM correctly identified the TCGA pan-cancer study, retrieved mutation data for TP53 and KRAS, selected appropriate patient groups, found survival attributes, and retrieved survival data. However, it failed to perform the actual Kaplan-Meier survival analysis and log-rank test for statistical significance, instead only providing descriptive statistics. The approach included many exploratory queries that could have been consolidated, but the final analysis logic is sound for the descriptive portion."
        }
    },
    "14": {
        "question": "Does Tylenol cause cancer?",
        "response_brief": {
            "missing_steps": [],
            "extra_steps": [],
            "steps_to_queries_mapping": {},
            "completeness": 3,
            "conciseness": 3,
            "correctness": 3,
            "comments": "The LLM correctly identified that this question is out of scope for the cBioPortal database and cannot be answered with SQL queries. The expected step confirms that no queries can be constructed, and the LLM appropriately provided an explanation instead of attempting to create irrelevant queries. The response is accurate, complete, and appropriately concise."
        }
    },
    "15": {
        "question": "Are there studies that were not processed using polyA enrichment in order to explore lncRNA-related questions?",
        "response_brief": {
            "missing_steps": [
                "Step 0: No queries can be constructed to answer this question with the cBioPortal database"
            ],
            "extra_steps": [
                "Query 1: Search for RNA/sequencing related clinical attributes",
                "Query 2: Alternative search for clinical attributes",
                "Query 3: Search for library preparation attributes",
                "Query 4: Count attribute values for genome libraries",
                "Query 5: Alternative count of attribute values",
                "Query 6: Search for RNA-related attributes with counts",
                "Query 7: Search for studies with RNA sequencing data",
                "Query 8: Search genetic profiles for polyA/ribosomal mentions",
                "Query 9: Search for ribosomal depletion profiles",
                "Query 10: Find RNA expression profiles without polyA",
                "Query 11: Focus on TCGA studies with RNA profiles",
                "Query 12: Find non-TCGA studies with RNA data",
                "Query 13: Count samples in specific studies",
                "Query 14: Alternative sample counting approach",
                "Query 15: Simple sample count for selected studies"
            ],
            "steps_to_queries_mapping": {},
            "completeness": 1,
            "conciseness": 1,
            "correctness": 1,
            "comments": "The expected step clearly states that no queries can be constructed to answer this question with the cBioPortal database, indicating this is out of scope. However, the LLM proceeded to execute 15 different queries attempting to find information about RNA sequencing library preparation methods and polyA enrichment, which directly contradicts the expected approach. While the LLM's queries are technically sound and explore relevant database tables, they fundamentally ignore the expected conclusion that this question cannot be answered with cBioPortal data."
        }
    },
    "16": {
        "question": "In the Breast Invasive Carcinoma TCGA study what are the top 5 down-regulated genes in TP53 mutated samples compared to non-mutated ones?",
        "response_brief": {
            "missing_steps": [],
            "extra_steps": [
                "Query 1: Study identification",
                "Query 2-3: Profile identification",
                "Query 4-6: Sample counting and validation",
                "Query 10: Profile type exploration",
                "Query 13-14: Gene annotation lookup"
            ],
            "steps_to_queries_mapping": {
                "1": "1",
                "2": "7,8,9,11,12",
                "3": "7,8,9,11,12",
                "4": "7,8,9,11,12"
            },
            "completeness": 3,
            "conciseness": 1,
            "correctness": 3,
            "comments": "All expected steps are present and correctly implemented. The core analysis is performed in queries 7-12 which identify TP53 mutation status, retrieve expression data, compare groups, and rank down-regulated genes. However, there are many extra queries for validation, exploration, and annotation that while useful, are not strictly necessary for answering the question. The final results correctly identify the top 5 down-regulated genes with proper statistical comparisons."
        }
    }
}